Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced NMPA clearance for two pivotal clinical studies evaluating adebrelimab, its anti-PD-L1 monoclonal antibody, in perioperative settings for gastrointestinal malignancies. The approvals enable a Phase II/III trial in locally advanced resectable rectal cancer (adebrelimab + SHR-8068 + chemoradiotherapy) and a Phase III trial in resectable gastric/gastroesophageal junction (GEJ) cancer (adebrelimab + SOX chemotherapy vs. placebo), expanding the PD-L1 franchise beyond its 2023 SCLC approval into curative-intent solid tumor indications.
Neoadjuvant immunotherapy to increase pathologic complete response (pCR) rates; potential for organ preservation (watch-and-wait)
Gastric/GEJ Cancer
Perioperative chemotherapy (FLOT or SOX)
Addition of PD-L1 blockade to SOX backbone; improved R0 resection rates and recurrence-free survival
Perioperative Immunotherapy Trend:
Neoadjuvant setting: Larger tumor antigen burden for immune priming; opportunity to assess early response (pCR as surrogate)
Adjuvant setting: Elimination of micrometastatic disease; improved long-term survival
China Market: Gastric cancer incidence highest globally; rectal cancer rising with Westernized diets
Competitive Landscape
Competitor
Product
Indication
Status
Hengrui Differentiation
BMS
Opdivo + Yervoy (nivo/ipi)
MSI-H colorectal (adjuvant)
Approved
Adebrelimab/SHR-8068 targets MSS rectal (larger population); SOX combo for gastric
AstraZeneca
Imfinzi + tremelimumab
Gastric/GEJ (1L)
Phase III
Perioperative positioning vs. first-line metastatic
Merck
Keytruda (pembro)
Gastric/GEJ (MSI-H)
Approved
Adebrelimab targets broader population (all-comer perioperative)
Hengrui
Adebrelimab + SHR-8068/SOX
Rectal, Gastric/GEJ (perioperative)
Phase II/III
China-first development; cost-competitive domestic mAb manufacturing
Strategic Outlook
2026-2027: Patient enrollment initiation; pCR data readouts anticipated 2028
Regulatory Pathway: NDA submissions 2029-2030 contingent on event-free survival benefits
Commercial Synergy: Leverages Hengrui’s established oncology sales force (SCLC launch infrastructure)
Global Ambitions: U.S./EU IND preparation ongoing; perioperative gastric data may support FDA breakthrough application
Forward‑Looking Statements This brief contains forward‑looking statements regarding clinical development timelines, perioperative immunotherapy efficacy, and regulatory pathways for adebrelimab. Actual results may differ due to competitive dynamics with checkpoint inhibitor combinations, surgical standard-of-care evolution, and manufacturing scale.-Fineline Info & Tech
By Fineline Cube